ResearchMoz

Humalog (Type 2 Diabetes) - Analysis and Forecasts to 2020

GlobalData
Published Date » 2012-01-31
No. Of Pages » 44


GlobalDatas pharmaceuticals report, Humalog (Type 2 Diabetes) Analysis and Forecasts to 2020 provides Humalog sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Type 2 Diabetes market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Humalog including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Humalog including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2011-2020 for Humalog in each of the seven major markets
Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of Content

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 4

2 Introduction 5
2.1 Diabetes 5
2.2 Epidemiology 5
2.2.1 Prevalence 5
2.2.2 Mortality 7
2.3 Etiology and Risk Factors 9
2.3.1 Obesity 9
2.3.2 Sedentary Lifestyle 9
2.3.3 Family History and Genetics 9
2.3.4 Ethnicity 9
2.3.5 Old Age 9
2.4 Economic Impact of Diabetes 9
2.5 GlobalData Report Guidance 11

3 Type 2 Diabetes: Market Characterization 12
3.1 Type 2 Diabetes Market 12
3.2 Type 2 Diabetes Market Forecasts 13
3.3 Type 2 Diabetes Market: Drivers and Restraints 14
3.3.1 Drivers 14
3.3.2 Restraints 15

4 Classification of Diabetes 16
4.1 Types of Diabetes 16
4.1.1 Type 1 Diabetes 16
4.1.2 Type 2 Diabetes 16
4.1.3 Gestational Diabetes 16
4.2 Diabetes Complications 16
4.2.1 Cardiovascular Disease 16
4.2.2 Nephropathy 17
4.2.3 Neuropathy 17
4.2.4 Amputation 17
4.2.5 Retinopathy 17
5 Evolution of Anti-Diabetic Treatments 18

6 Medications 20
6.1 Insulin 20
6.2 Oral Medications 20
6.2.1 Sulfonylureas (SUR) 20
6.2.2 Biguanides (BGDs) 20
6.2.3 Alpha-Glucosidase Inhibitors (AGI) 22
6.2.4 Meglitinides 22
6.2.5 Thiazolidinediones (TZDs) 23
6.2.6 Dipeptidyl Peptidase IV (DPP- 4) Inhibitors 24
6.2.7 Oral Combination Therapy 24
6.3 Other Injectionable Medications 25
6.3.1 Pramlintide 25
6.3.2 Exenatide 25
6.4 Market Share as per Classes in Type 2 Diabetes 25

7 Humalog (insulin lispro) 26
7.1 Introduction 26
7.2 Mechanism of Action 26
7.3 Clinical Studies 26
7.3.1 Safety & Efficacy Study in Humalog & Humulin R 26
7.3.2 Comparison of Means of Glycemic Parameters 27
7.3.3 Combination Therapy 27
7.4 Approval History of Humalog 28
7.5 Factors Affecting Sales of Humalog 28
7.5.1 Growing Insulin Market 28
7.5.2 First in Class 28
7.5.3 Advantage of Humalog over Regular Insulin 28
7.5.4 Prevention of Spiking Blood Sugar between Meals 28
7.5.5 Effective Treatment for Low Blood Sugar at Night 28
7.6 Drug Evaluation 29
7.6.1 Drug Risk Benefit Score 29
7.6.2 Intensity of Competition 30
7.7 Sales Estimates 30
7.7.1 Target Patient Pool for Humalog 30
7.7.2 Dosing 30
7.7.3 Market Penetration 31
7.7.4 Annual Cost of Therapy 31
7.7.5 Sales Projections of Humalog 32

8 Diabetes Market: Appendix 41
8.1 Market Definitions 41
8.2 List of Abberiviations 41
8.3 Research Methodology 41
8.3.1 Coverage 42
8.3.2 Secondary Research 42
8.3.3 Forecasting 42
8.3.4 Number of patients approved to take the drug 42
8.3.5 Net Penetration of Drug 43
8.3.6 Net Annual Dosing 43
8.3.7 Annual Cost of Therapy 43
8.4 Drug Sales Estimates Model 43
8.5 Contact Us 43
8.6 Disclaimer 44
8.7 Sources 44

List of Tables


Table 1: Diabetes, World, Prevalence Estimates for the age group 20-79 years (million), 2000-2030 5
Table 2: Diabetes, Top 10 Countries, by Prevalence (million), 2010 and 2030 7
Table 3: Diabetes, Top 10 Countries, Highest Health Expenditures ($bn), 2010 10
Table 4: Type 2 Diabetes, World, Major Marketed Drugs By Sales ($m), 2010 12
Table 5: Type 2 Diabetes, World, Major Pipeline Products in Phase III 13
Table 6: Diabetes, Worldwide, Prevalence Estimates, 2010 and 2030 14
Table 7: Overweight*, Global, Prevalence Estimates in Males Aged 15 and above (%), 2005 15
Table 8: Diabetes Drugs Evolution 19
Table 9: Type 2 Diabetes Mellitus Adults 26
Table 10: Comparison of Means of Glycemic Parameters at the end of Combined Treatment periods (3 months for each treatment) 27
Table 11: Results of a Two Month Study in which Humalog was added to Sulfonylurea therapy in Patients not adequately controlled on Sulfonylureas alone 27
Table 12: Approval of Humalog 28
Table 13: Drug Risk Benefit Score, Humalog 29
Table 14: Drug Risk Benefit Score, Humalog Mix 75/25 29
Table 15: Humalog, Annual Cost of Therapy in Type 2 Diabetes, Global, 2011 31
Table 16: Humalog Mix 75/25, Annual Cost of Therapy in Type 2 Diabetes, Global, 2011 31
Table 17: Humalog franchise, Annual Cost of Therapy in Type 2 Diabetes, Global, 2011 31
Table 18: Humalog, Type 2 Diabetes, Global, Sales Estimates ($m), 20022020 32
Table 19: Humalog, Type 2 Diabetes, The US, Sales Estimates ($m), 20022020 33
Table 20: Humalog, Type 2 Diabetes, The UK, Sales Estimates ($m), 20022020 34
Table 21: Humalog, Type 2 Diabetes, France, Sales Estimates ($m), 20022020 35
Table 22: Humalog, Type 2 Diabetes, Germany, Sales Estimates ($m), 20022020 36
Table 23: Humalog, Type 2 Diabetes, Italy, Sales Estimates ($m), 20022020 37
Table 24: Humalog, Type 2 Diabetes, Spain, Sales Estimates ($m), 20022020 38
Table 25: Humalog, Type 2 Diabetes, Japan, Sales Estimates ($m), 20022020 39

List of Figures


Figure 1: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2010 6
Figure 2: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2030 6
Figure 3: Diabetes, World, Mortality, 2010 7
Figure 4: Top 10 Causes of Mortality, Worldwide, 2008 8
Figure 5: Type 2 Diabetes, Global, Market Size Forecasts ($bn), 20102020 13
Figure 6: Mechanism of Action of Sulfonylureas 20
Figure 7: Mechanism of Action of Biguanide, Thiazolidinediones, Alpha-Glucosidase Inhibitors 21
Figure 8: Mechanism of Action of Metformin and Alpha-Glucosidase Inhibitors 22
Figure 9: Mechanism of Action of Thiazolidinediones 23
Figure 10: Mechanism of Action of DPP IV Inhibitors 24
Figure 11: Type 2 Diabetes, Global, Market Share by Value, By Class (%), 2010 25
Figure 12: Humalog, Type 2 Diabetes, Global, Sales Estimates ($m), 2002-2020 32
Figure 13: Humalog, Type 2 Diabetes, The US, Sales Estimates ($m), 20022020 33
Figure 14: Humalog, Type 2 Diabetes, The UK, Sales Estimates ($m), 20022020 34
Figure 15: Humalog, Type 2 Diabetes, France, Sales Estimates ($m), 20022020 35
Figure 16: Humalog, Type 2 Diabetes, Germany, Sales Estimates ($m), 20022020 36
Figure 17: Humalog, Type 2 Diabetes, Italy, Sales Estimates ($m), 20022020 37
Figure 18: Humalog, Type 2 Diabetes, Spain, Sales Estimates ($m), 20022020 38
Figure 19: Humalog, Type 2 Diabetes, Japan, Sales Estimates ($m), 2002-2020 39
Figure 20: Humalog, Type 2 Diabetes, Sales Distribution by Country (%), 2020 40
Figure 21: Patients Approved for the Drug 43

Upcoming Reports:

Apoptosis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
By - Transparency Market Research
Apoptosis is a programmed natural process of cell death in the body which results from natural stimuli in order to protect against viral infection, unusual cell division and cells with damaged genetic material. However malfunctioning of apoptosis can trigger uncontrolled and non regulated cell death related to degenerative disorders such as Parkinson’s disease and Alzheimer’s. Defective apoptosis process has been one of the most common and leading causes for cancer wherein the affected cells instead of undergoing apoptosis continue to proliferate and mutate. Thus...
Photocopiers Market - Global Industry Size, Market Share, Trends, Analysis And Forecasts, 2012 - 2018
By - Transparency Market Research
A photocopier is a machine that makes paper copies of documents and other visual images quickly and cheaply. Photocopying is widely used in business, education, and government. The biggest differentiators in the industry are the penetration, distribution strength and efficient after-sales-support. The photocopier demand has been to a large extent fuelled by the growth in the services sector, with banks and multinational companies leading the way. The future is likely to be in developing India as a manufacturing base and in providing comprehensive services to customers....
Antibiotic Market - Global Industry Size, Share, Trends, Analysis And Forecast, 2012 - 2018
By - Transparency Market Research
An antibiotic is a compound or a substance that fights bacterial infections and kills or slow down their growth. The antibiotic market is witnessing high growth due new product innovations and higher investment in R & D activity. Moreover, the other regulatory concerns to control the antibiotic resistance problem are also expected to drive the antibiotics market. The demand for antibiotics is expected to reach USD 44.68 billion by 2016. Since, 2005 this market is seen to grow at an annual rate of 6.6% until 2011. There are many companies manufacturing antibiotic these days...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.com
Select License type:

Share this report

Related News

New Drug Shows Early Promise against Heart Attacks and Strokes
Sep 1, 2014  
Sanofi and Regeneron Pharmaceuticals have been working on a new experimental drug that aims to lower cholesterol. Early tests have shown that the drug cuts down risks of heart attacks and strokes in clinical trials by half. The test report says that the results are not conclusive as the analysis was performed retrospectively. The study does provide the positive result that...
New Materials Creation Strategy
Sep 1, 2014  
Scientists always aim at theorizing about new compounds and materials; however after Researchers have made use of X-ray scattering in a process known as molecular beam epitaxy (MBE) to understand atom behavior as a kind of material called as layered oxides were getting formed. For computational predictions of new materials, the available observations were utilized for providing insights on...
Western Africa economies hit by Ebola travel ban
Aug 28, 2014  
With over 1,400 people dead due to the fatal Ebola outbreak in African countries, travel services have either banned or limited operations to the western region, severely hitting economies of the area. Budgetary resources are being utilized rapidly and economic growth has dropped by 4% as international projects and trips have been cancelled. Transport companies have cut off the region...
Fonterra Ties Up With Beingmate to Tap into China’s Baby Food Market
Aug 28, 2014  
Fonterra Co-Operative Group Ltd. will partner with Beingmate Group Co, China’s biggest infant formula manufacturer to increase its reach in the Chinese market. The New Zealand-based company makes this move with the intent to grab a bigger market share in China after it suffered many setbacks in the food-safety scandal last year.   This partnership will also help Beingmate...
Chinas Leading Asset-Management Company Aims for IPO
Aug 28, 2014  
China’s biggest asset-management company plans to go public by the end of 2015. Chinese authorities are constantly ramping up their interests towards introducing mixed ownership to state-owned huge companies and call for more private capital investments into the economy. According to the news report, China Huarong Asset Management Co., Ltd. will collaborate with eight investors...